1242145-12-5Relevant articles and documents
Discovery of (3 S,3a R)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5- tetrahydro-2 H -benzo[ g ]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy
Meyers, Marvin J.,Arhancet, Graciela B.,Hockerman, Susan L.,Chen, Xiangyang,Long, Scott A.,Mahoney, Matthew W.,Rico, Joseph R.,Garland, Danny J.,Blinn, James. R.,Collins, Joe T.,Yang, Shengtian,Huang, Horng-Chih,McGee, Kevin F.,Wendling, Jay M.,Dietz, Jessica D.,Payne, Maria A.,Homer, Bruce L.,Heron, Marcia I.,Reitz, David B.,Hu, Xiao
experimental part, p. 5979 - 6002 (2010/11/02)
We have discovered a novel class of nonsteroidal pyrazoline antagonists of the mineralocorticoid receptor (MR) that show excellent potency and selectivity against other nuclear receptors. Early analogues were poorly soluble and had a propensity to inhibit the hERG channel. Remarkably, both of these challenges were overcome by incorporation of a single carboxylate moiety. Structural modification of carboxylate-containing lead R-4g with a wide range of substituents at each position of the pyrazoline ring resulted in R-12o, which shows excellent activity against MR and reasonable pharmacokinetic profile. Introduction of conformational restriction led to a novel series characterized by exquisite potency and favorable steroid receptor selectivity and pharmacokinetic profile. Oral dosing of 3S,3aR-27d (PF-3882845) in the Dahl salt sensitive preclinical model of salt-induced hypertension and nephropathy showed blood pressure attenuation significantly greater than that with eplerenone, reduction in urinary albumin, and renal protection. As a result of these findings, 3S,3aR-27d was advanced to clinical studies.